Table 2 Network meta-analysis of efficacy and safety outcomes of new antidiabetic drug classes using random-effects model
From: Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
MACE | |||
 GLP-1 RA | 1.01 (0.92–1.12) | 1.14 (1.04–1.26) | 1.14 (1.07–1.22) |
 0.99 (0.89–1.09) | SGLT-2 inhibitor | 1.13 (1.02–1.25) | 1.13 (1.05–1.22) |
 0.88 (0.80–0.96) | 0.89 (0.80–0.98) | DPP-4 inhibitor | 1.00 (0.94–1.07) |
 0.87 (0.82–0.93) | 0.88 (0.82–0.95) | 1.00 (0.93–1.07) | Placebo |
Nonfatal myocardial infarction | |||
 GLP-1 RA | 1.04 (0.88–1.23) | 1.13 (0.97–1.32) | 1.11 (1.00–1.24) |
 0.96 (0.81–1.13) | SGLT-2 inhibitor | 1.08 (0.91–1.29) | 1.07 (0.94–1.22) |
 0.88 (0.78–1.04) | 0.92 (0.77–1.10) | DPP-4 inhibitor | 0.98 (0.88–1.11) |
 0.90 (0.81–1.00) | 0.94 (0.82–1.07) | 1.02 (0.90–1.14) | Placebo |
Nonfatal stroke | |||
 GLP-1 RA | 1.17 (0.98–1.41) | 1.12 (0.93–1.35) | 1.14 (1.01–1.29) |
 0.85 (0.71–1.02) | SGLT-2 inhibitor | 0.95 (0.79–1.16) | 0.97 (0.85–1.11) |
 0.89 (0.74–1.08) | 1.05 (0.87–1.27) | DPP-4 inhibitor | 1.02 (0.89–1.18) |
 0.88 (0.77–0.99) | 1.03 (0.90–1.17) | 0.98 (0.85–1.13) | Placebo |
Cardiovascular mortality | |||
 GLP-1 RA | 0.93 (0.78–1.11) | 1.11 (0.93–1.33) | 1.13 (0.99–1.28) |
 1.08 (0.90–1.29) | SGLT-2 inhibitor | 1.20 (1.01–1.42) | 1.22 (1.08–1.38) |
 0.90 (0.75–1.07) | 0.83 (0.70–0.99) | DPP-4 inhibitor | 1.02 (0.90–1.15) |
 0.89 (0.78–1.01) | 0.82 (0.73–0.93) | 0.98 (0.87–1.11) | Placebo |
All-cause mortality | |||
 GLP-1 RA | 0.93 (0.82–1.06) | 1.13 (0.99–1.28) | 1.11 (1.02–1.22) |
 1.07 (0.94–1.22) | SGLT-2 inhibitor | 1.20 (1.06–1.37) | 1.19 (1.09–1.30) |
 0.89 (0.78–1.01) | 0.83 (0.73–0.94) | DPP-4 inhibitor | 0.99 (0.91–1.08) |
 0.90 (0.82–0.99) | 0.84 (0.77–0.92) | 1.01 (0.93–1.10) | Placebo |
Hospitalisation for heart failure | |||
 GLP-1 RA | 0.79 (0.69–0.90) | 1.22 (1.08–1.37) | 1.15 (1.08–1.22) |
 1.27 (1.11–1.45) | SGLT-2 inhibitor | 1.55 (1.33–1.81) | 1.46 (1.30–1.64) |
 0.82 (0.73–0.92) | 0.64 (0.55–0.75) | DPP-4 inhibitor | 0.94 (0.85–1.04) |
 0.87 (0.82–0.93) | 0.68 (0.61–0.77) | 1.06 (0.96–1.18) | Placebo |
Renal composite outcome | |||
 GLP-1 RA | 0.69 (0.59–0.80) | 1.16 (1.03–1.31) | 1.16 (1.06–1.27) |
 1.46 (1.25–1.70) | SGLT-2 inhibitor | 1.69 (1.46–1.96) | 1.70 (1.50–1.91) |
 0.86 (0.76–0.98) | 0.59 (0.51–0.69) | DPP-4 inhibitor | 1.00 (0.92–1.09) |
 0.86 (0.78–0.94) | 0.59 (0.52–0.67) | 1.00 (0.92–1.08) | Placebo |